ArticleCancer biology & medicine2019
Clinicopathologic and molecular characteristics of 44 patients with pure secretory breast carcinoma.
Article in Cancer biology & medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Mammary secretory carcinoma in a female domestic rabbit (Oryctolagus cuniculus): histopathological and immunohistochemical features.Veterinary research communications · 2026Article
- Secretory carcinoma of the breast: a report of six cases with different immunophenotypes and molecular subtypes.Histopathology · 2026Article
- Case report: Secretory carcinoma of the breast with ETV6-NTRK3 fusion: clinicopathological features and molecular confirmation by FISH in two cases.Frontiers in oncology · 2026Article
- Secretory breast carcinoma: morphologic and molecular heterogeneity with indicators of aggressive potential in a cohort of 29 cases.The journal of pathology. Clinical research · 2025Article
- A rare ER-positive secretory breast carcinoma: diagnostic challenges and surgical treatment.Annals of medicine and surgery (2012) · 2025Article
- Secretory breast carcinoma: a multicenter clinicopathologic study of 80 cases with emphasis on prognostic analysis and chemotherapy benefit.Breast cancer research and treatment · 2025Article
- Secretory Carcinoma of the Breast with Apocrine Differentiation-A Peculiar Entity.Medicina (Kaunas, Lithuania) · 2024Article
- Prognosis of primary breast salivary gland-type carcinoma: a propensity score-matching analysis with invasive carcinoma of no special type based on the SEER database for years 2010-2020.Breast cancer (Tokyo, Japan) · 2024Article
- Secretory breast carcinoma: clinicopathological features and prognosis of 52 patients.Breast cancer research and treatment · 2024Article
- Advancement of secretory breast carcinoma: a narrative review.Annals of translational medicine · 2022Review
- Metastatic triple negative breast cancer with NTRK gene fusion on tissue but not on ctDNA molecular profile.BMJ case reports · 2022Article
- Secretory Carcinoma of the Breast Mimicking Invasive Ductal Carcinoma: A Case Report.The American journal of case reports · 2022Article
- Cytological and molecular characterization of secretory breast carcinoma.Diagnostic cytopathology · 2022Review
- Review
- Secretory breast carcinoma in a female adult with liver metastsis: a case report and literature review.Diagnostic pathology · 2021Review
- Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast.Scientific reports · 2021Article
- Triple-negative breast cancer: A run-through of features, classification and current therapies.Oncology letters · 2021Review
- Secretory carcinoma of the breast, commonly exhibits the features of low grade, triple negative breast carcinoma- A Case report with updated review of literature.Autopsy & case reports · 2021Article
- Triple negative breast cancer: special histological types and emerging therapeutic methods.Cancer biology & medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSecretory breast carcinoma (SBC) is a rare type of breast malignancy, accounting for less than 0.02% of all infiltrating breast malignancies. The pure SBC, a type of SBC without another type of breast malignant neoplasm, is particularly rare. This study aimed to investigate the clinicopathologic and molecular features of pure SBC.
methodsThe main pathological parameters such as estrogen receptor (ER), progesterone receptor (PR), and human epithelial growth factor receptor 2 (C-erbB-2) were detected by immunohistochemistry (IHC), and the clinicopathologic and prognostic difference were compared with invasive ductal carcinoma (IDC). Fluorescent
resultsWe found that the positivity rates of ER, PR, C-erbB-2, p53, and S-100 were 47.7% (21/44), 52.3% (23/44), 36.4% (16/44), 27.3% (12/44), and 95.5% (42/44), respectively, which were higher than those reported in previous studies. Special periodic acid-Schiff analysis was performed in 36 patients, and the value of the Ki-67 index ranged from 1% to 50% (mean value: 10%). Interestingly, most patients with pure SBC harbored an ETV6-NTRK3 rearrangement with an 88.6% (39/44) expression rate. Compared with IDC, the tumor size of most patients with SBC was larger than 2 cm (
conclusionsAlthough axillary lymph node metastasis, local recurrence, or distant metastasis may occur, SBC is also considered an indolent neoplasm with a good prognosis. Once diagnosed, surgical treatment should be performed as soon as possible, followed by appropriate adjuvant chemotherapy, irradiation, and endocrine therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.